Literature DB >> 10942501

Cardiotoxic transplacental effect of idarubicin administered during the second trimester of pregnancy.

C Achtari1, P Hohlfeld.   

Abstract

Polychemotherapy including idarubicin was administered during the second trimester to treat acute lymphoblastic leukemia. The infant delivered at 28 weeks' gestation had acute cardiac failure attributed to the cardiotoxic effect of idarubicin. Cardiotoxicity may be caused by idarubicin's biophysical properties that facilitate its transplacental passage. Idarubicin should be used with extreme caution during pregnancy.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10942501     DOI： 10.1067/mob.2000.105964

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN： 0002-9378            Impact factor:   8.661


  5 in total

Review 1.  Pregnancy and renal failure: the case for application of dosage guidelines.

Authors:  F Keller; M Griesshammer; U Häussler; W Paulus; A Schwarz
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 2.  Transplacental Passage and Fetal Effects of Antineoplastic Treatment during Pregnancy.

Authors:  Silvia Triarico; Serena Rivetti; Michele Antonio Capozza; Alberto Romano; Palma Maurizi; Stefano Mastrangelo; Giorgio Attinà; Antonio Ruggiero
Journal:  Cancers (Basel)       Date:  2022-06-24       Impact factor: 6.575

3.  [Diagnosis and treatment of acute leukemia during pregnancy].

Authors:  N Peng; M Y Liang; Q Jiang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2022-01-14

Review 4.  Epirubicin: a new entry in the list of fetal cardiotoxic drugs? Intrauterine death of one fetus in a twin pregnancy. Case report and review of literature.

Authors:  Marialuisa Framarino-dei-Malatesta; Giuseppina Perrone; Antonella Giancotti; Flavia Ventriglia; Martina Derme; Isabella Iannini; Valentina Tibaldi; Paola Galoppi; Paolo Sammartino; Gianluca Cascialli; Roberto Brunelli
Journal:  BMC Cancer       Date:  2015-12-16       Impact factor: 4.430

Review 5.  Does anthracycline-based chemotherapy in pregnant women with cancer offer safe cardiac and neurodevelopmental outcomes for the developing fetus?

Authors:  Marialuisa Framarino-Dei-Malatesta; Paolo Sammartino; Angela Napoli
Journal:  BMC Cancer       Date:  2017-11-21       Impact factor: 4.430
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.